J P Morgan Chase & Co Reaffirms “Neutral” Rating for GlaxoSmithKline PLC (GSK)

GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating reissued by equities research analysts at J P Morgan Chase & Co in a research report issued on Tuesday, October 24th.

A number of other research analysts have also recently commented on the company. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Wednesday, October 18th. Morgan Stanley lowered GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a report on Friday, September 8th. Argus reiterated a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline PLC in a report on Thursday, August 31st. BidaskClub upgraded GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Finally, Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company. GlaxoSmithKline PLC has a consensus rating of “Hold” and a consensus price target of $44.33.

Shares of GlaxoSmithKline PLC (GSK) opened at $35.30 on Tuesday. The company has a market capitalization of $86,814.73, a PE ratio of 12.52, a P/E/G ratio of 1.96 and a beta of 1.00. GlaxoSmithKline PLC has a 52-week low of $35.08 and a 52-week high of $44.53. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/12/glaxosmithkline-plc-gsk-earns-neutral-rating-from-jpmorgan-chase-co.html.

In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the company’s stock in a transaction on Monday, November 6th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.00% of the company’s stock.

Large investors have recently bought and sold shares of the business. FMR LLC grew its stake in shares of GlaxoSmithKline PLC by 5.9% during the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after purchasing an additional 1,389,238 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of GlaxoSmithKline PLC by 2.3% during the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after purchasing an additional 293,866 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of GlaxoSmithKline PLC by 112.1% during the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after purchasing an additional 4,935,900 shares in the last quarter. Hotchkis & Wiley Capital Management LLC grew its stake in shares of GlaxoSmithKline PLC by 4.3% during the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after purchasing an additional 322,700 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of GlaxoSmithKline PLC by 15.8% during the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after purchasing an additional 934,928 shares in the last quarter. Institutional investors and hedge funds own 9.29% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply